Actively Recruiting
Comparing Sphenopalatine Block and BOTOX Treatments for Adults with Chronic Migraine
Led by Cairo University · Updated on 2025-05-16
64
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of sphenopalatine ganglion block SPGB compared to intramuscular Botulinum Toxin Type A BOTOX injections in people with chronic migraine. Migraines are classified as primary headaches and involve complex nerve interactions. The study aims to compare these two treatments to better understand their effects on migraine pain. Participants are randomly assigned to one of two groups one receiving 2 ml of 2% lidocaine administered via a nasal applicator in each nostril as the sphenopalatine block, and the other receiving 100 units of Botulinum Toxin Type A injected at fixed sites. Both treatments are given once, and the study does not use masking or blinding. During the 12 weeks after treatment, participants will have their pain levels assessed to measure treatment impact. Researchers will also track the percentage of patients free from headache and the rate of headache relief. The study involves regular monitoring of symptoms and treatment effects over this period to evaluate and compare both interventions.
CONDITIONS
Brief Title
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Research Team
M
Mohamed E Abdel Fattah, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
